Cell & Cellular Life Sciences Journal
Research Article
1 min read
The Mingled Allies-Combined Hepatocellular Carcinoma and Cholangiocarcinoma
* Corresponding author
Keywords
Neoplasm
Hepatocellular Carcinoma
Hepatic Cirrhosis
Fibrotic Stroma
Cholangiocarcinoma
Abstract
Combined hepatocellular carcinoma and cholangiocarcinoma is an exceptionally discerned, primary malignant neoplasm incriminating the hepatic parenchyma. Neoplasm categorically exhibits an amalgamation of dual hepatocellular and biliary differentiation within a singular neoplasm. Notwithstanding, collision tumours do not configure as combined lesions.
Figures
![Figure 1: Combined hepatocellular carcinoma and cholangiocarcinoma composed of cuboidal cells impregnated with pale, pink cytoplasm, intermingled with glandular articulations layered with malignant epithelium and an encompassing fibrotic stroma [5].](/fulltextimages/11767/fig_1.png)
Click to enlarge
![Figure 2: Combined hepatocellular and cholangiocarcinoma demonstrating cuboidal cells pervaded with abundant eosinophilic cytoplasm and commingled glandular structures layered with malignant epithelium and circumscribing fibrotic stroma [6].](/fulltextimages/11767/fig_2.png)
Click to enlarge
Tables
| WHO classification 4th edition | WHO classification 5th edition | |
|---|---|---|
| combined hepatocellular carcinoma and cholangiocarcinoma-classical type | combined hepatocellular carcinoma and cholangiocarcinoma-classical type | |
| combined hepatocellular carcinoma and cholangiocarcinoma with stem cell features-classical type | intermediate cell carcinoma | |
| combined hepatocellular carcinoma and cholangiocarcinoma with stem cell features- intermediate type | classified with cholangiocarcinoma | |
| combined hepatocellular carcinoma and cholangiocarcinoma with stem cell features- cholangiocellular type | classified with cholangiocarcinoma |
Table 1: Contemporary World Health Organization (WHO) classification of combined hepatocellular carcinoma and cholangiocarcinoma
References
-
Roßner F, Sinn BV, Horst D (2023) Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update. Cancers (Basel) 15(2): 494.
-
Amory B, Goumard C, Laurent A, Langella S, Cherqui D, et al. (2023) AFC-ICC-2009, AFC-LLR-2018, and PRS-2019 Study Group. Combined hepatocellular- cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching. Surgery 175(2): 413-423.
-
Lv TR, Hu HJ, Ma WJ, Liu F, Jin YW, et al. (2023) Meta- analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma. Eur J Surg Oncol 50(1): 107279.
-
Kim J, Joo DJ, Hwang S, Lee JM, Ryu JH, et al. (2023) Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study. World J Gastrointest Surg 15(7): 1340-1353.
-
Image 1 Courtesy: Pathology outlines.
-
Image 2 Courtesy: Research gate.
-
Penzkofer L, Gröger LK, Hoppe-Lotichius M, Baumgart J, Heinrich F, et al. (2023) Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center. Cancers (Basel) 15(3): 639.
← Previous Article
Compilation and Embodiment-Leydig Cell Tumour Testis
Next Article →
Reprogramming of GLP-1 Response at Prediabetes for the
Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1
Receptor Agonists
More from this journal
- The Muculent Bleb-Mucinous Cystic Neoplasm-Hepatobiliary Region
- Insulin Sensitizers as Anti-Aging Agents: Unveiling Synergies with Albumin, GLP-1RA, Klotho Protein, and Metformin in the Quest to Combat Aging
- Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists
- Compilation and Embodiment-Leydig Cell Tumour Testis
- Glucolipotoxicity: A Novel Different Perspective on the Causes of Cancer
- Semaglutide, a GLP-1 Agonist Like 'Ozempic' and its Potential Role as a Preventive Anti-Cancer Agent